Results 161 to 170 of about 376,342 (317)

Trastuzumab in metastatic breast cancer.

open access: yesEuropean journal of gynaecological oncology, 2006
Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to 30%
TOMAO, FEDERICA   +5 more
openaire   +2 more sources

Consumed by Abdominal Distention

open access: yes
Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge   +3 more
wiley   +1 more source

HNRNPU K181 Lactylation Drives Cervical Cancer Growth by Upregulating PHGDH and Reprogramming Serine Metabolism

open access: yesAdvanced Science, EarlyView.
Lactate in cervical cancer induces HNRNPU K181 lactylation, opposed by NAA50‐mediated acetylation and suppressed by Pazopanib. This lactylation enhances HNRNPU binding to PHGDH pre‐mRNA exon 1, maintaining exon 1‐containing transcripts and mRNA stability, thereby activating serine metabolism.
Chang Zhang   +6 more
wiley   +1 more source

TSPYL5 Promotes Triple‐Negative Breast Cancer Metastasis by Antagonizing USP10‐Mediated PTEN Stabilization to Unleash a ZEB1‐Dependent EMT Program

open access: yesAdvanced Science, EarlyView.
The hyperactivation of PI3K/AKT signaling in PTEN wild‐type triple‐negative breast cancer represents a clinical paradox. We delineate a novel post‐translational regulatory axis wherein the oncogene TSPYL5 competitively antagonizes the deubiquitinase USP10.
Jiaying Shi   +8 more
wiley   +1 more source

A Bioinspired Three‐Dimensional High‐Curvature Nano‐Interface Integrated Microfluidic Chip for Small Extracellular Vesicles Enrichment and Machine Learning‐Assisted Prostate Cancer Precision Diagnosis

open access: yesAdvanced Science, EarlyView.
A biotin‐modified artificial insertion peptide functionalized three‐dimensional high‐curvature‐TiO2 nano‐interface was engineered in a microfluidic chip to improve the isolation efficiency of small extracellular vesicles (sEVs). This chip balanced affinity, releasability, and extendibility, enabling high‐throughput recovery of sEVs for downstream ...
Le Wang   +7 more
wiley   +1 more source

Microarray analysis of tamoxifen resistance in breast cancer.

open access: yes, 2009
PhDTamoxifen remains a widely used hormone therapy for pre and postmenopausal women with hormone receptor positive breast cancer in both adjuvant and metastatic disease settings. Resistance to this well tolerated and cost-effective drug limits its use.
Moss, Charlotte
core  

Cancer‐Associated Fibroblasts Promote Tumor Immunosuppression in Hepatocellular Carcinoma via the NNMT‐ANGPTL4 Axis

open access: yesAdvanced Science, EarlyView.
ABSTRACT Background & Aims: Cancer‐associated fibroblasts (CAFs) drive immunosuppression in hepatocellular carcinoma (HCC). However, their metabolic regulation remains poorly defined. We investigated the role of nicotinamide N‐methyltransferase (NNMT) in CAFs. Approach & Results: High NNMT expression in CAF tissues was confirmed by western blotting and
Shounan Lu   +20 more
wiley   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou   +12 more
wiley   +1 more source

Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer. [PDF]

open access: yesESMO Open
Salehi E   +17 more
europepmc   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy